FR2640638B1
(fr)
|
1988-12-20 |
1991-02-15 |
Commissariat Energie Atomique |
Bioreacteur et dispositif pour la culture de cellules animales
|
AU7906691A
(en)
|
1990-05-23 |
1991-12-10 |
United States of America, as represented by the Secretary, U.S. Department of Commerce, The |
Adeno-associated virus (aav)-based eucaryotic vectors
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
US5587308A
(en)
|
1992-06-02 |
1996-12-24 |
The United States Of America As Represented By The Department Of Health & Human Services |
Modified adeno-associated virus vector capable of expression from a novel promoter
|
US6268213B1
(en)
|
1992-06-03 |
2001-07-31 |
Richard Jude Samulski |
Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
|
US5693531A
(en)
|
1993-11-24 |
1997-12-02 |
The United States Of America As Represented By The Department Of Health And Human Services |
Vector systems for the generation of adeno-associated virus particles
|
JPH10501686A
(ja)
|
1994-04-13 |
1998-02-17 |
ザ ロックフェラー ユニヴァーシティ |
神経系の細胞へのdnaのaav仲介送達
|
US20020159979A1
(en)
|
1994-06-06 |
2002-10-31 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
US5658785A
(en)
|
1994-06-06 |
1997-08-19 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
US6204059B1
(en)
|
1994-06-30 |
2001-03-20 |
University Of Pittsburgh |
AAV capsid vehicles for molecular transfer
|
US5856152A
(en)
|
1994-10-28 |
1999-01-05 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV vector and methods of use therefor
|
US5625048A
(en)
|
1994-11-10 |
1997-04-29 |
The Regents Of The University Of California |
Modified green fluorescent proteins
|
WO1996017947A1
(fr)
|
1994-12-06 |
1996-06-13 |
Targeted Genetics Corporation |
Lignees cellulaires d'encapsidation utilisees pour la generation de titres hauts de vecteurs aav recombinants
|
US5652224A
(en)
|
1995-02-24 |
1997-07-29 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
|
US5741657A
(en)
|
1995-03-20 |
1998-04-21 |
The Regents Of The University Of California |
Fluorogenic substrates for β-lactamase and methods of use
|
US5756283A
(en)
|
1995-06-05 |
1998-05-26 |
The Trustees Of The University Of Pennsylvania |
Method for improved production of recombinant adeno-associated viruses for gene therapy
|
US6281010B1
(en)
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
US5688676A
(en)
|
1995-06-07 |
1997-11-18 |
Research Foundation Of State University Of New York |
In vitro packaging of adeno-associated virus DNA
|
US5741683A
(en)
|
1995-06-07 |
1998-04-21 |
The Research Foundation Of State University Of New York |
In vitro packaging of adeno-associated virus DNA
|
US6197293B1
(en)
|
1997-03-03 |
2001-03-06 |
Calydon, Inc. |
Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
|
US6676935B2
(en)
|
1995-06-27 |
2004-01-13 |
Cell Genesys, Inc. |
Tissue specific adenoviral vectors
|
US6143548A
(en)
|
1995-08-30 |
2000-11-07 |
Genzyme Corporation |
Chromatographic purification of adeno-associated virus (AAV)
|
US6265389B1
(en)
|
1995-08-31 |
2001-07-24 |
Alkermes Controlled Therapeutics, Inc. |
Microencapsulation and sustained release of oligonucleotides
|
US5846528A
(en)
|
1996-01-18 |
1998-12-08 |
Avigen, Inc. |
Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
|
US5858351A
(en)
|
1996-01-18 |
1999-01-12 |
Avigen, Inc. |
Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
|
US5962313A
(en)
|
1996-01-18 |
1999-10-05 |
Avigen, Inc. |
Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
|
US5952221A
(en)
|
1996-03-06 |
1999-09-14 |
Avigen, Inc. |
Adeno-associated virus vectors comprising a first and second nucleic acid sequence
|
US7026468B2
(en)
|
1996-07-19 |
2006-04-11 |
Valentis, Inc. |
Process and equipment for plasmid purification
|
EP0931158A1
(fr)
|
1996-09-06 |
1999-07-28 |
The Trustees Of The University Of Pennsylvania |
Procede inductible de production de virus adeno-associes recombines au moyen de la polymerase t7
|
US6083716A
(en)
|
1996-09-06 |
2000-07-04 |
The Trustees Of The University Of Pennsylvania |
Chimpanzee adenovirus vectors
|
ATE465267T1
(de)
|
1996-09-06 |
2010-05-15 |
Univ Pennsylvania |
Rekombinante aav zur herstellung eines medikaments für die gentherapie von muskelzellen
|
US5866552A
(en)
|
1996-09-06 |
1999-02-02 |
The Trustees Of The University Of Pennsylvania |
Method for expressing a gene in the absence of an immune response
|
IL128736A0
(en)
|
1996-09-06 |
2000-01-31 |
Univ Pennsylvania |
Methods using cre-lox for production of recombinant adeno-associated viruses
|
US20020037867A1
(en)
|
1999-02-26 |
2002-03-28 |
James M. Wilson |
Method for recombinant adeno-associated virus-directed gene therapy
|
EP0932694A2
(fr)
|
1996-09-11 |
1999-08-04 |
THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Vecteur de vaa4 et ses utilisations
|
US7732129B1
(en)
|
1998-12-01 |
2010-06-08 |
Crucell Holland B.V. |
Method for the production and purification of adenoviral vectors
|
DE69737107T2
(de)
|
1996-11-20 |
2007-07-12 |
Introgen Therapeutics Inc., Austin |
Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
|
WO1998027204A2
(fr)
|
1996-12-18 |
1998-06-25 |
Targeted Genetics Corporation |
Genes d'encapsidation fractionnes de virus adeno-associe (aav) et lignees cellulaires comprenant ces genes utilises pour la production de vecteurs d'aav de recombinaison
|
US6156303A
(en)
|
1997-06-11 |
2000-12-05 |
University Of Washington |
Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
|
US6710036B2
(en)
|
1997-07-25 |
2004-03-23 |
Avigen, Inc. |
Induction of immune response to antigens expressed by recombinant adeno-associated virus
|
US6251677B1
(en)
|
1997-08-25 |
2001-06-26 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
US6566118B1
(en)
|
1997-09-05 |
2003-05-20 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
US6989264B2
(en)
|
1997-09-05 |
2006-01-24 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
CA2304168A1
(fr)
|
1997-09-19 |
1999-04-01 |
The Trustees Of The University Of Pennsylvania |
Procedes et lignee cellulaire utiles pour la production de virus adeno-associes recombines
|
CA2303768C
(fr)
|
1997-09-19 |
2009-11-24 |
The Trustees Of The University Of Pennsylvania |
Procedes et produits genetiques vectoriels utiles pour obtenir un virus adeno-associe (aav)
|
CA2304131A1
(fr)
|
1997-09-19 |
1999-04-01 |
James M. Wilson |
Procede de transfert de gene utilisant bcl2 et compositions utiles a cet effet
|
US6642051B1
(en)
|
1997-10-21 |
2003-11-04 |
Targeted Genetics Corporation |
Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
|
IT1297074B1
(it)
|
1997-11-21 |
1999-08-03 |
Angeletti P Ist Richerche Bio |
Forme ormone-dipendenti delle proteine rep del virus adeno-associato (aav-2), sequenze di dna codificanti per esse, vettori che le
|
CA2316414A1
(fr)
|
1997-12-23 |
1999-07-01 |
Introgene B.V. |
Virus de recombinaison chimeriques faits d'un adenovirus et d'un virus adeno-associe utiles pour l'integration d'informations genetiques etrangeres dans l'adn chromosomique de cellules cibles
|
US6410300B1
(en)
|
1998-01-12 |
2002-06-25 |
The University Of North Carolina At Chapel Hill |
Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
|
WO1999043360A1
(fr)
|
1998-02-26 |
1999-09-02 |
The Trustees Of The University Of Pennsylvania |
Protection stable contre la degenerescence sarcolemmique dystrophique et retablissement du complexe sarcoglycane
|
US6953690B1
(en)
|
1998-03-20 |
2005-10-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
US6521426B1
(en)
|
1998-04-08 |
2003-02-18 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Preparation of recombinant adenovirus carrying a rep gene of adeno-associated virus
|
FR2778413B1
(fr)
|
1998-05-07 |
2000-08-04 |
Immunotech Sa |
Nouveaux reactifs et methode de lyse des erythrocytes
|
EP1078096A1
(fr)
|
1998-05-11 |
2001-02-28 |
Ariad Gene Therapeutics, Inc. |
Compositions multivirales et utilisations de celles-ci
|
US6436392B1
(en)
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
EP1849872A1
(fr)
|
1998-05-20 |
2007-10-31 |
University Of Iowa Research Foundation |
Vecteurs de virus adéno associés et leur utilisation
|
US6146874A
(en)
|
1998-05-27 |
2000-11-14 |
University Of Florida |
Method of preparing recombinant adeno-associated virus compositions
|
AU4185699A
(en)
|
1998-05-27 |
1999-12-13 |
Avigen, Inc. |
Adeno-associated viral vector-mediated expression of factor viii activity
|
WO1999061601A2
(fr)
|
1998-05-28 |
1999-12-02 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Vecteurs d'aav5 et leurs utilisation
|
US6984517B1
(en)
|
1998-05-28 |
2006-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
AAV5 vector and uses thereof
|
GB2338236B
(en)
|
1998-06-13 |
2003-04-09 |
Aea Technology Plc |
Microbiological cell processing
|
US6900049B2
(en)
|
1998-09-10 |
2005-05-31 |
Cell Genesys, Inc. |
Adenovirus vectors containing cell status-specific response elements and methods of use thereof
|
US6416992B1
(en)
|
1998-10-13 |
2002-07-09 |
Avigen, Inc. |
Compositions and methods for producing recombinant adeno-associated virus
|
US6200560B1
(en)
|
1998-10-20 |
2001-03-13 |
Avigen, Inc. |
Adeno-associated virus vectors for expression of factor VIII by target cells
|
EP1124976A1
(fr)
|
1998-10-27 |
2001-08-22 |
Crucell Holland B.V. |
Production amelioree de vecteurs de virus associes aux adenovirus
|
US6759237B1
(en)
|
1998-11-05 |
2004-07-06 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
|
US6689600B1
(en)
|
1998-11-16 |
2004-02-10 |
Introgen Therapeutics, Inc. |
Formulation of adenovirus for gene therapy
|
US6759050B1
(en)
|
1998-12-03 |
2004-07-06 |
Avigen, Inc. |
Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
|
US6225113B1
(en)
|
1998-12-04 |
2001-05-01 |
Genvec, Inc. |
Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
|
US6387368B1
(en)
|
1999-02-08 |
2002-05-14 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
DE19905501B4
(de)
|
1999-02-10 |
2005-05-19 |
MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie |
Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
|
US6509150B1
(en)
|
1999-03-05 |
2003-01-21 |
Universite De Nantes |
Compositions and methods for recombinant Adeno-Associated Virus production
|
JP4693244B2
(ja)
|
1999-03-18 |
2011-06-01 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
|
US6258595B1
(en)
|
1999-03-18 |
2001-07-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
CA2368194A1
(fr)
|
1999-04-30 |
2000-11-09 |
University Of Florida |
Ribozymes fournis par virus adeno-associes pour la decouverte de fonctions geniques
|
EP1183380A1
(fr)
|
1999-06-02 |
2002-03-06 |
The Trustees Of The University Of Pennsylvania |
Compositions et methodes pour la fabrication de virus recombines necessitant des virus auxiliaires
|
CA2376400A1
(fr)
|
1999-06-08 |
2000-12-14 |
University Of Iowa Research Foundation |
Composes et procedes permettant d'ameliorer la transduction de raav
|
CA2382483A1
(fr)
|
1999-08-20 |
2001-03-01 |
Johns Hopkins University School Of Medicine |
Techniques et compositions permettant de construire et d'utiliser des bibliotheques de fusion
|
US6365394B1
(en)
|
1999-09-29 |
2002-04-02 |
The Trustees Of The University Of Pennsylvania |
Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
|
JP2003523320A
(ja)
|
1999-09-29 |
2003-08-05 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ウイルスベクターの迅速なpeg改変方法、高められた遺伝子形質導入のための組成物、高められた物理的安定性を伴う組成物、およびそのための用途
|
US7241447B1
(en)
|
1999-10-07 |
2007-07-10 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors and uses thereof
|
CA2386546A1
(fr)
|
1999-10-07 |
2001-04-12 |
University Of Iowa Research Foundation |
Virus adeno-associe et utilisations correspondantes
|
WO2001032711A2
(fr)
|
1999-10-21 |
2001-05-10 |
Board Of Trustees Of The University Of Arkansas |
Proteine regulatrice majeure rep78 de virus associe aux adenovirus aav, mutants de cette proteine et utilisations associees
|
AU3642601A
(en)
|
1999-11-05 |
2001-05-30 |
Avigen, Inc. |
Ecdysone-inducible adeno-associated virus expression vectors
|
US6582692B1
(en)
|
1999-11-17 |
2003-06-24 |
Avigen, Inc. |
Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
|
AU1954001A
(en)
|
1999-12-10 |
2001-06-18 |
Ariad Gene Therapeutics, Inc. |
Methods for high level expression of genes in primates
|
US7638120B2
(en)
|
2000-03-14 |
2009-12-29 |
Thomas Jefferson University |
High transgene expression of a pseudotyped adeno-associated virus type
|
CA2373110A1
(fr)
|
2000-03-14 |
2001-09-20 |
Neurologix, Inc. |
Production de vecteurs de capsides chimeres
|
US6855314B1
(en)
|
2000-03-22 |
2005-02-15 |
The United States Of America As Represented By The Department Of Health And Human Services |
AAV5 vector for transducing brain cells and lung cells
|
US6468524B1
(en)
|
2000-03-22 |
2002-10-22 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
AAV4 vector and uses thereof
|
US7048920B2
(en)
|
2000-03-24 |
2006-05-23 |
Cell Genesys, Inc. |
Recombinant oncolytic adenovirus for human melanoma
|
AU2001249622B2
(en)
|
2000-03-30 |
2007-06-07 |
Massachusetts Institute Of Technology |
RNA sequence-specific mediators of RNA interference
|
GB0009887D0
(en)
|
2000-04-20 |
2000-06-07 |
Btg Int Ltd |
Cytotoxic agents
|
AU2001255575B2
(en)
|
2000-04-28 |
2006-08-31 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
|
US7125705B2
(en)
|
2000-04-28 |
2006-10-24 |
Genzyme Corporation |
Polynucleotides for use in recombinant adeno-associated virus virion production
|
US20030013189A1
(en)
|
2000-04-28 |
2003-01-16 |
Wilson James M. |
Compositions and methods useful for non-invasive delivery of therapeutic molecules to the bloodstream
|
AU2001268373A1
(en)
|
2000-06-13 |
2001-12-24 |
The Children's Hospital Of Philadelphia |
Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
|
EP1302542B1
(fr)
|
2000-07-18 |
2007-06-13 |
Takeda Pharmaceutical Company Limited |
Nouveau peptide actif sur le plan physiologique et utilisation associee
|
US6593123B1
(en)
|
2000-08-07 |
2003-07-15 |
Avigen, Inc. |
Large-scale recombinant adeno-associated virus (rAAV) production and purification
|
US6329181B1
(en)
|
2000-08-07 |
2001-12-11 |
Neurologix, Inc. |
Helper functions for recombinant vector production
|
ES2288993T3
(es)
|
2000-08-17 |
2008-02-01 |
Keiya Ozawa |
Distribucion de factores angiogenicos mediada por virus adenoasociados.
|
DE10044384A1
(de)
|
2000-09-08 |
2002-04-18 |
Medigene Ag |
Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung
|
FR2813891B1
(fr)
|
2000-09-14 |
2005-01-14 |
Immunotech Sa |
Reactif multifonctionnel pour erythrocytes mettant en jeu des carbamates et applications
|
JP2002153278A
(ja)
|
2000-11-22 |
2002-05-28 |
Hisamitsu Pharmaceut Co Inc |
ウイルスベクターの製造に用いられる細胞、その製法およびその細胞を用いたウイルスベクターの製造方法
|
WO2002070719A2
(fr)
|
2001-01-19 |
2002-09-12 |
Trustees Of The University Of Pennsylvania |
Systeme d'expression genique regulable
|
FR2821624B1
(fr)
*
|
2001-03-01 |
2004-01-02 |
Sod Conseils Rech Applic |
Nouveau polynucleotide utilisable pour moduler la proliferation des cellules cancereuses
|
JP2004532822A
(ja)
|
2001-03-14 |
2004-10-28 |
アビジェン, インコーポレイテッド |
ビリオンの管逆行感染による組換えアデノ随伴ウイルス媒介遺伝子移入
|
US20060217331A1
(en)
*
|
2001-05-18 |
2006-09-28 |
Sirna Therapeutics, Inc. |
Chemically modified double stranded nucleic acid molecules that mediate RNA interference
|
US7344872B2
(en)
|
2001-06-22 |
2008-03-18 |
The Trustees Of The University Of Pennsylvania |
Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
|
US20040136963A1
(en)
|
2001-06-22 |
2004-07-15 |
The Trustees Of The University Of Pennsylvania |
Simian adenovirus vectors and methods of use
|
EP1900815B1
(fr)
|
2001-07-12 |
2016-09-07 |
University of Massachusetts |
Production in vivo de petits ARN interférents qui modèrent le silençage génique
|
WO2003006477A1
(fr)
|
2001-07-12 |
2003-01-23 |
University Of Massachusetts |
Production in vivo of small interfering rnas that mediate gene silencing
|
US8241622B2
(en)
|
2001-07-13 |
2012-08-14 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
|
EP1279740A1
(fr)
|
2001-07-26 |
2003-01-29 |
Vrije Universiteit Brussel |
Vector recombinant dérivé d'un virus-adéno-associé pour l'utilisation thérapie génique
|
JP2004538005A
(ja)
|
2001-08-08 |
2004-12-24 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
シアル酸に結合するタンパク質を有するウイルスベクターの精製法
|
US20030092161A1
(en)
|
2001-09-19 |
2003-05-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for production of recombinant viruses, and uses therefor
|
EP2385123B1
(fr)
|
2001-09-28 |
2018-04-25 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Molécules de micro arn
|
AU2002360355B2
(en)
|
2001-11-09 |
2005-07-07 |
Government Of The United States Of America, Department Of Health And Human Services |
Production of adeno-associated virus in insect cells
|
US6723551B2
(en)
|
2001-11-09 |
2004-04-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Production of adeno-associated virus in insect cells
|
NZ532635A
(en)
|
2001-11-13 |
2007-05-31 |
Univ Pennsylvania |
A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
|
EP1944043A1
(fr)
|
2001-11-21 |
2008-07-16 |
The Trustees of the University of Pennsylvania |
Séquences d'acides aminés et d'acides nucléiques d'adénovirus simien, vecteurs les contenant, et procédés d'utilisation.
|
NZ532383A
(en)
|
2001-11-21 |
2007-03-30 |
Univ Pennsylvania |
Pan-7 simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
|
JP4550421B2
(ja)
|
2001-12-12 |
2010-09-22 |
メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド |
ウイルスの保存のための組成物
|
AU2002359284A1
(en)
|
2001-12-17 |
2003-06-30 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
|
PT1453547T
(pt)
|
2001-12-17 |
2016-12-28 |
Univ Pennsylvania |
Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
|
AU2002359786A1
(en)
|
2001-12-19 |
2003-07-09 |
Hiroaki Mizukami |
Adeno-associated virus-mediated delivery of gdnf to skeletal muscles
|
US8110351B2
(en)
|
2002-01-16 |
2012-02-07 |
Invitrogen Dynal As |
Method for isolating nucleic acids and protein from a single sample
|
GB0208390D0
(en)
|
2002-04-11 |
2002-05-22 |
Univ London |
Adeno-associated virus producer system
|
US20030198620A1
(en)
|
2002-04-16 |
2003-10-23 |
Keiya Ozawa |
Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions
|
EP1359217B1
(fr)
|
2002-04-29 |
2006-12-13 |
The Trustees of The University of Pennsylvania |
Méthode pour l'amplification et production des virus intégrés dans l'ADN cellulaire de tissu
|
BR0309659A
(pt)
|
2002-04-30 |
2005-02-22 |
Oncolytics Biotech Inc |
Método para produzir vìrus de uma cultura de células, composição, e, método para produzir reovìrus infeccioso
|
DE60323078D1
(de)
|
2002-05-01 |
2008-10-02 |
Univ Florida |
Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteine
|
ES2465574T3
(es)
|
2002-05-03 |
2014-06-06 |
Duke University |
Un método para regular la expresión génica
|
DE60335672D1
(de)
|
2002-05-14 |
2011-02-17 |
Merck Sharp & Dohme |
Verfahren zur reinigung von adenovirus
|
US7419817B2
(en)
|
2002-05-17 |
2008-09-02 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. |
Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
|
WO2003104413A2
(fr)
|
2002-06-05 |
2003-12-18 |
University Of Florida |
Production de virions de virus adeno-associe (aav) recombinants pseudo-types
|
US20040241854A1
(en)
|
2002-08-05 |
2004-12-02 |
Davidson Beverly L. |
siRNA-mediated gene silencing
|
US20080274989A1
(en)
*
|
2002-08-05 |
2008-11-06 |
University Of Iowa Research Foundation |
Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
|
US20050255086A1
(en)
|
2002-08-05 |
2005-11-17 |
Davidson Beverly L |
Nucleic acid silencing of Huntington's Disease gene
|
WO2004027030A2
(fr)
|
2002-09-18 |
2004-04-01 |
Isis Pharmaceuticals, Inc. |
Reduction efficace d'arn cibles au moyen de composes oligomeres a brin simple et double
|
EP1418185A1
(fr)
|
2002-11-11 |
2004-05-12 |
Aventis Pharma Deutschland GmbH |
Utilisation du récepteur EDG2 dans un modèle animal de crise cardiaque
|
US7169612B2
(en)
|
2002-11-11 |
2007-01-30 |
Sanofi-Aventis Deutschland Gmbh |
Use of EDG2 receptor in an animal model of heart failure
|
US7618948B2
(en)
|
2002-11-26 |
2009-11-17 |
Medtronic, Inc. |
Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
|
AU2004265550A1
(en)
|
2003-02-21 |
2005-02-24 |
The Penn State Research Foundation |
RNA interference compositions and methods
|
WO2004075861A2
(fr)
|
2003-02-26 |
2004-09-10 |
Children's Hospital, Inc. |
Production de virus recombines adeno associes
|
WO2004083441A2
(fr)
|
2003-03-19 |
2004-09-30 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Bibliotheque peptidique aleatoire s'affichant sur des vecteurs aav
|
WO2004108922A2
(fr)
|
2003-04-25 |
2004-12-16 |
The Trustees Of The University Of Pennsylvania |
Procedes et compositions pour abaisser le niveaux totaux de cholesterol et traitement des maladies cardiaques
|
US7589189B2
(en)
|
2003-05-14 |
2009-09-15 |
Japan Science And Technology Agency |
Inhibition of the expression of huntingtin gene
|
US8927269B2
(en)
|
2003-05-19 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Avian adenoassociated virus and uses thereof
|
ES2521682T3
(es)
|
2003-05-21 |
2014-11-13 |
Genzyme Corporation |
Procedimientos para producir preparaciones de viriones de AAV recombinantes sustancialmente exentas de cápsidas vacías
|
ATE485394T1
(de)
*
|
2003-06-02 |
2010-11-15 |
Univ Massachusetts |
Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai
|
EP1486567A1
(fr)
|
2003-06-11 |
2004-12-15 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Vecteur derivé d'un virus associé aux adenovirus pour la thérapie génique
|
JP4888876B2
(ja)
|
2003-06-13 |
2012-02-29 |
田平 武 |
アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
|
PL2657248T3
(pl)
|
2003-06-19 |
2017-09-29 |
Genzyme Corporation |
Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
|
EP1636370B1
(fr)
|
2003-06-20 |
2014-04-16 |
The Trustees of The University of Pennsylvania |
Procede pour produire des adenovirus chimeriques et utilisations de ces derniers
|
US7291498B2
(en)
|
2003-06-20 |
2007-11-06 |
The Trustees Of The University Of Pennsylvania |
Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
EP1649028B1
(fr)
|
2003-07-25 |
2012-08-22 |
Genvec, Inc. |
Vaccins a base de vecteurs adenoviraux
|
CA2533701A1
(fr)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants
|
US7947658B2
(en)
*
|
2003-09-12 |
2011-05-24 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
DK2292780T3
(en)
|
2003-09-30 |
2017-12-04 |
Univ Pennsylvania |
Clades and sequences of adeno-associated virus (AAV), vectors containing them, and uses thereof
|
US7962316B2
(en)
|
2003-10-27 |
2011-06-14 |
Merck Sharp & Dohme Corp. |
Method of designing siRNAs for gene silencing
|
DE602005026269D1
(de)
|
2004-04-28 |
2011-03-24 |
Univ Pennsylvania |
Sequenzielle freisetzung immunogener moleküle über adenoviren und adeno-assoziierte viren vermittelte abgaben
|
MX360727B
(es)
|
2004-06-01 |
2018-11-14 |
Genzyme Corp |
Composiciones y metodos para evitar la agregacion del vector aav.
|
JP2008503590A
(ja)
|
2004-06-21 |
2008-02-07 |
メドトロニック・インコーポレーテッド |
組成物を細胞にデリバリーするための医学用システム及び方法
|
DK1807009T3
(en)
|
2004-10-05 |
2015-03-02 |
Genzyme Corp |
Stair shaped needle
|
JPWO2006043354A1
(ja)
|
2004-10-20 |
2008-05-22 |
独立行政法人放射線医学総合研究所 |
組込型の低線量放射線誘導性ベクター
|
US7901921B2
(en)
|
2004-10-22 |
2011-03-08 |
Oncolytics Biotech Inc. |
Viral purification methods
|
AU2005307737C1
(en)
|
2004-11-18 |
2013-08-29 |
The Board Of Trustees Of The University Of Illinois |
Multicistronic siRNA constructs to inhibit tumors
|
CN1286981C
(zh)
|
2004-11-30 |
2006-11-29 |
华中科技大学同济医学院附属同济医院 |
表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法
|
CA2596588C
(fr)
|
2005-01-31 |
2017-06-27 |
University Of Iowa Research Foundation |
Silencage nucleique de gene de maladie d'huntington
|
EP1844145A2
(fr)
|
2005-02-03 |
2007-10-17 |
Benitec, Inc. |
Produits de synthese d'expression d'arni
|
US8614101B2
(en)
|
2008-05-20 |
2013-12-24 |
Rapid Pathogen Screening, Inc. |
In situ lysis of cells in lateral flow immunoassays
|
US7625570B1
(en)
|
2005-03-10 |
2009-12-01 |
The Regents Of The University Of California |
Methods for purifying adeno-associated virus
|
WO2006102072A2
(fr)
|
2005-03-23 |
2006-09-28 |
The Trustees Of The University Of Pennsylvania |
Utilisation d'un polypeptide pa131 dans le traitement de l'atherosclerose
|
WO2006110689A2
(fr)
|
2005-04-07 |
2006-10-19 |
The Trustees Of The University Of Pennsylvania |
Procede d'augmentation de la fonction d'un vecteur aav
|
WO2006119432A2
(fr)
|
2005-04-29 |
2006-11-09 |
The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services |
Isolation, clonage, et caracterisation de nouveaux serotypes de virus adeno-associes (avv)
|
EP1879624B1
(fr)
|
2005-05-02 |
2011-09-21 |
Genzyme Corporation |
Therapie genique pour des troubles neurometaboliques
|
CA2619534A1
(fr)
|
2005-08-18 |
2007-02-22 |
Alnylam Pharmaceuticals, Inc. |
Methodes et compositions pour le traitement de maladies neurologiques
|
JP5238503B2
(ja)
|
2005-08-23 |
2013-07-17 |
ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア |
対流増加送達を用いた治療薬の慢性的な送達のための逆流防止カニューレ及びシステム
|
EP1857552A1
(fr)
|
2006-05-20 |
2007-11-21 |
Cargill Incorporated |
Xylose isomérase thermostable
|
AU2006304997B2
(en)
|
2005-10-20 |
2012-03-01 |
Uniqure Ip B.V. |
Improved AAV vectors produced in insect cells
|
CA2627025A1
(fr)
*
|
2005-10-28 |
2007-05-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions et methodes destinees a inhiber l'expression du gene huntingtine
|
EP2007795B1
(fr)
|
2006-03-30 |
2016-11-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Protéines de capsides aav
|
KR101407707B1
(ko)
|
2006-04-03 |
2014-06-19 |
산타리스 팔마 에이/에스 |
Anti-mirna 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물
|
DE602007004470D1
(de)
|
2006-04-28 |
2010-03-11 |
Univ Pennsylvania |
Modifiziertes adenovirus-hexon-protein und anwendungen davon
|
JP2009535339A
(ja)
|
2006-04-28 |
2009-10-01 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
低下されたキャプシド免疫原性を有する改変aavベクターおよびその使用
|
CN101528916B
(zh)
|
2006-04-28 |
2013-09-04 |
宾夕法尼亚大学托管会 |
规模可调的aav生产方法
|
WO2007130519A2
(fr)
|
2006-05-02 |
2007-11-15 |
Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Microréseau d'acide nucléique viral et procédé d'utilisation
|
JP5551432B2
(ja)
|
2006-05-25 |
2014-07-16 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
遺伝子不活性化のための方法と組成物
|
EP3705577A1
(fr)
|
2006-06-21 |
2020-09-09 |
uniQure IP B.V. |
Vecteurs aav avec des séquences de codage rep améliorées pour la production de cellules d'insectes
|
WO2008011636A2
(fr)
|
2006-07-21 |
2008-01-24 |
California Institute Of Technology |
Administration de gène ciblée pour une vaccination des cellules dendritiques
|
CN101501193B
(zh)
*
|
2006-08-11 |
2013-07-03 |
普罗森那技术公司 |
用于治疗与dna重复不稳定性相关的遗传病的方法和手段
|
CN101522903B
(zh)
|
2006-08-24 |
2013-07-31 |
威洛克有限公司 |
具有重叠开放阅读框的基因在昆虫细胞中的表达及其方法和组合物
|
EP2097095B1
(fr)
|
2006-11-29 |
2016-01-27 |
Nationwide Children's Hospital |
Inhibition de la myostatine destinée à améliorer le muscle et/ou à améliorer la fonction musculaire
|
CA2670967C
(fr)
|
2006-11-29 |
2016-05-10 |
University Of Iowa Research Foundation |
Voies d'export alternatives pour l'interference d'arn exprimee par vecteur
|
EP3492596A1
(fr)
|
2007-04-09 |
2019-06-05 |
University of Florida Research Foundation, Inc. |
Compositions de vecteur raav comprenant des protéines de capside à tyrosine modifié et procédés d'utilisation
|
US9611302B2
(en)
|
2007-04-09 |
2017-04-04 |
University Of Florida Research Foundation, Inc. |
High-transduction-efficiency RAAV vectors, compositions, and methods of use
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
WO2008128251A1
(fr)
|
2007-04-17 |
2008-10-23 |
The Children's Hospital Of Philadelphia |
Vecteur viral humanisé et procédés pour d'utilisation
|
WO2008134646A2
(fr)
|
2007-04-26 |
2008-11-06 |
University Of Iowa Research Foundation |
Suppression de l'interférence par l'arn des maladies neurodégénératives et ses méthodes d'utilisation
|
EP2158211B1
(fr)
|
2007-05-31 |
2016-08-10 |
Medigene AG |
Protéine structurale mutée d'un parvovirus
|
WO2008150897A2
(fr)
|
2007-05-31 |
2008-12-11 |
University Of Iowa Research Foundation |
Réduction de la toxicité de l'interférence arn hors cible
|
EP2012122A1
(fr)
|
2007-07-06 |
2009-01-07 |
Medigene AG |
Protéines structurelles de parvovirus muté
|
US8841437B2
(en)
|
2008-06-20 |
2014-09-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Precursor miRNA loop-modulated target regulation
|
AU2008271658B8
(en)
|
2007-06-29 |
2013-07-04 |
F. Hoffmann-La Roche Ag |
Promoter
|
DK2176283T3
(en)
|
2007-07-14 |
2017-02-13 |
Univ Iowa Res Found |
METHODS AND COMPOSITIONS FOR TREATMENT OF BRAIN DISEASES
|
EP2019143A1
(fr)
|
2007-07-23 |
2009-01-28 |
Genethon |
Thérapie génique du CNS utilisant l'administration périphérique de vecteurs AAV
|
JP5634262B2
(ja)
|
2007-07-26 |
2014-12-03 |
ユニキュアー アイピー ビー.ブイ. |
差次的コドンバイアスを有する反復コード配列を含むバキュロウイルスベクター
|
JP2010537640A
(ja)
|
2007-08-27 |
2010-12-09 |
ボストン バイオメディカル, インコーポレイテッド |
マイクロrna模倣剤または阻害剤としての非対称性rna二重鎖の組成物
|
WO2009030025A1
(fr)
|
2007-09-04 |
2009-03-12 |
Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health |
Virus adéno-associés porcins
|
JP2010538675A
(ja)
|
2007-09-19 |
2010-12-16 |
アムステルダム モレキュラー セラピューティクス ビー.ブイ. |
タンパク質産生の改善のためのaav複製機構の使用
|
BRPI0819774A2
(pt)
|
2007-11-28 |
2014-10-14 |
Univ Pennsylvania |
Subfamília c de adenovírus sadv-40, -31 e -34 de símio e seus usos
|
DK2220241T3
(en)
|
2007-11-28 |
2017-01-09 |
Univ Pennsylvania |
Adenovirus comprising a simian adenovirus E-SAdV-39-capsidhexonprotein and uses thereof
|
HUE031636T2
(en)
|
2007-11-28 |
2017-07-28 |
Univ Pennsylvania |
SAdV-28,27, -29, -32, -33, and -34 simian B subgenus adenoviruses
|
AU2009209408B2
(en)
|
2008-01-29 |
2015-06-11 |
Beacon Therapeutics Limited |
Recombinant virus production using mammalian cells in suspension
|
ES2929031T3
(es)
|
2008-02-19 |
2022-11-24 |
Uniqure Ip Bv |
Optimización de la expresión de las proteínas rep y cap parvovirales en células de insecto
|
JP5661476B2
(ja)
|
2008-03-04 |
2015-01-28 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
サルアデノウイルスSAdV−36、−42.1、−42.2および−44ならびにそれらの用途
|
US8632764B2
(en)
|
2008-04-30 |
2014-01-21 |
University Of North Carolina At Chapel Hill |
Directed evolution and in vivo panning of virus vectors
|
WO2009134681A2
(fr)
|
2008-04-30 |
2009-11-05 |
The Trustees Of The University Of Pennsylvania |
Vecteurs viraux aav7 pour une administration ciblée de cellules rpe
|
CN105920216A
(zh)
*
|
2008-05-09 |
2016-09-07 |
西奈山医学院 |
用于预防和治疗神经退行性疾病的方法
|
GB2472964B
(en)
|
2008-05-20 |
2013-04-24 |
Eos Neuroscience Inc |
Vectors for delivery of light-sensitive proteins and methods of use
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
WO2009154452A1
(fr)
|
2008-06-17 |
2009-12-23 |
Amsterdam Molecular Therapeutics B.V. |
Capside parvovirale avec région de répétition gly-ala incorporée
|
US8945885B2
(en)
|
2008-07-03 |
2015-02-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Minicircle DNA vector preparations and methods of making and using the same
|
US8212019B2
(en)
|
2008-07-30 |
2012-07-03 |
University Of Massachusetts |
Nucleic acid silencing sequences
|
CA2738969A1
(fr)
|
2008-09-29 |
2010-04-01 |
Amsterdam Molecular Therapeutics (Amt) B.V. |
Therapie genique par la porphobilinogene desaminase
|
KR20110081862A
(ko)
|
2008-10-22 |
2011-07-14 |
제넨테크, 인크. |
축삭 변성의 조절
|
EP2350269B1
(fr)
|
2008-10-31 |
2015-09-09 |
The Trustees Of The University Of Pennsylvania |
Adénovirus simiens avec des proteines de capsides hexon de sadv-46 et leurs utilisations
|
US9415121B2
(en)
|
2008-12-19 |
2016-08-16 |
Nationwide Children's Hospital |
Delivery of MECP2 polynucleotide using recombinant AAV9
|
WO2010093784A2
(fr)
|
2009-02-11 |
2010-08-19 |
The University Of North Carolina At Chapel Hill |
Vecteurs viraux modifiés et procédés de fabrication et d'utilisation de ceux-ci
|
MX345729B
(es)
|
2009-03-04 |
2017-02-14 |
Deutsches Krebsforsch |
Proteina activadora del ensamblaje (aap) y su uso para la fabricacion de particulas de parvovirus que consisten esencialmente de vp3.
|
WO2010109053A1
(fr)
|
2009-03-27 |
2010-09-30 |
Proyeto De Biomedicina Cima, S.L. |
Méthodes et compositions pour le traitement de la cirrhose et de la fibrose hépatique
|
TR201906398T4
(tr)
|
2009-04-30 |
2019-05-21 |
Univ Pennsylvania |
Salgı bezleriyle ilişkili virüs yapılarını içeren iletken hava yolu hücrelerinin hedeflenmesine yönelik bileşimler.
|
EP2772542B1
(fr)
|
2009-05-28 |
2016-12-28 |
Deutsches Krebsforschungszentrum |
Polypeptides de capsides AAV modifiées
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
US8846031B2
(en)
|
2009-05-29 |
2014-09-30 |
The Trustees Of The University Of Pennsylvania |
Simian adenovirus 41 and uses thereof
|
KR101812813B1
(ko)
|
2009-06-16 |
2017-12-27 |
젠자임 코포레이션 |
재조합 aav 벡터에 대한 개선된 정제 방법
|
BR112012000421A2
(pt)
|
2009-07-06 |
2019-09-24 |
Alnylam Pharmaceuticals Inc |
composições e métodos para intensificar a produção de um produto biológico.
|
EP2451476A4
(fr)
|
2009-07-06 |
2013-07-03 |
Alnylam Pharmaceuticals Inc |
Biotraitement à base de cellules
|
RU2015133046A
(ru)
|
2009-07-15 |
2018-12-24 |
Кэлиммьюн Инк. |
Двойной вектор для подавления вируса иммунодефицита человека
|
EP2292781A1
(fr)
|
2009-08-17 |
2011-03-09 |
Genethon |
Production des produits biopharmaceutiques à base de Baculovirus dépourvus de virions baculoviraux contaminants
|
WO2011038187A1
(fr)
|
2009-09-25 |
2011-03-31 |
The Trustees Of The University Of Pennsylvania |
Diversification de virus adéno-associé (aav) commandé et bibliothèques préparées à partir de ce dernier
|
EP2498825B1
(fr)
|
2009-11-09 |
2017-03-29 |
Genepod Therapeutics Ab |
NOUVEAU VECTEUR VIRAL POUR LA SYNTHESE DE DOPA CONTINUÉE ET & xA;SPECIFIQUE AUX NEURONES IN VIVO
|
JP5697042B2
(ja)
|
2009-11-19 |
2015-04-08 |
国立大学法人 岡山大学 |
遺伝子発現を上昇させるシステム及び該システムを保持したベクター
|
WO2011069529A1
(fr)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Solution contenant du mannose pour la lyophilisation, la transfection et/ou l'injection d'acides nucléiques
|
WO2011088081A1
(fr)
|
2010-01-12 |
2011-07-21 |
The University Of North Carolina At Chapel Hill |
Répétitions terminales inversées restrictives pour vecteurs viraux
|
EP2531604B1
(fr)
|
2010-02-05 |
2017-04-05 |
The University of North Carolina At Chapel Hill |
Compositions et procédés d'amélioration de la transduction d'un parvovirus
|
EP3792348A3
(fr)
|
2010-03-11 |
2021-06-23 |
uniQure IP B.V. |
Séquences codant une protéine rep mutée destinées à être utilisées dans la production d'aav
|
US9546112B2
(en)
|
2010-03-22 |
2017-01-17 |
Association Institut De Myologie |
Methods of increasing efficiency of vector penetration of target tissue
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
SG183929A1
(en)
|
2010-03-29 |
2012-10-30 |
Univ Pennsylvania |
Pharmacologically induced transgene ablation system
|
WO2011122950A1
(fr)
|
2010-04-01 |
2011-10-06 |
Amsterdam Molecular Therapeutics (Amt) Ip B.V. |
Vecteurs aav duplex monomériques
|
EP2826860B1
(fr)
|
2010-04-23 |
2018-08-22 |
University of Massachusetts |
Vecteurs AAV de ciblage du système nerveux central et leurs procédés d'utilisation
|
CA3050894C
(fr)
|
2010-04-23 |
2022-10-18 |
University Of Massachusetts |
Constructions d'expression a cistrons multiples
|
WO2011133901A2
(fr)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Traitement à base d'aav pour des troubles liés au cholestérol
|
US8927514B2
(en)
|
2010-04-30 |
2015-01-06 |
City Of Hope |
Recombinant adeno-associated vectors for targeted treatment
|
US9839696B2
(en)
|
2010-04-30 |
2017-12-12 |
City Of Hope |
Recombinant adeno-associated vectors for targeted treatment
|
US8808684B2
(en)
|
2010-09-10 |
2014-08-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction
|
EP2612909B1
(fr)
|
2010-10-05 |
2015-02-25 |
Takara Bio, Inc. |
Procédé de production d'un vecteur viral
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
CN103189507A
(zh)
|
2010-10-27 |
2013-07-03 |
学校法人自治医科大学 |
用于向神经系统细胞导入基因的腺相关病毒粒子
|
EP2637702A4
(fr)
|
2010-11-11 |
2014-11-26 |
Univ Miami |
Procédés, compositions, cellules et kits pour traiter une lésion ischémique
|
EP2643465B1
(fr)
|
2010-11-23 |
2016-05-11 |
The Trustees Of The University Of Pennsylvania |
Adénovirus simiens de la sous-famille e a1321 et ses utilisations
|
US9181544B2
(en)
|
2011-02-12 |
2015-11-10 |
University Of Iowa Research Foundation |
Therapeutic compounds
|
ES2724800T3
(es)
|
2011-02-17 |
2019-09-16 |
Univ Pennsylvania |
Composiciones y métodos para alterar la especificidad de tejido y mejorar la transferencia génica mediada por AAV9
|
GB201103062D0
(en)
|
2011-02-22 |
2011-04-06 |
Isis Innovation |
Method
|
EP2500434A1
(fr)
|
2011-03-12 |
2012-09-19 |
Association Institut de Myologie |
Vecteurs AAV sans capside, compositions et procédés pour la production des vecteurs et la thérapie génique
|
JP6007463B2
(ja)
|
2011-04-18 |
2016-10-12 |
国立研究開発法人国立精神・神経医療研究センター |
薬剤送達粒子及びその製造方法
|
EP3699286A1
(fr)
|
2011-04-20 |
2020-08-26 |
The Trustees of the University of Pennsylvania |
Régimes et compositions pour l'immunisation passive médiée par aav contre des agents pathogènes en suspension dans l'air
|
JP6072772B2
(ja)
|
2011-04-22 |
2017-02-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
変異体キャプシドを有するアデノ関連ウイルスビリオンおよびその使用方法
|
WO2012149646A1
(fr)
|
2011-05-05 |
2012-11-08 |
Sunnybrook Research Institute |
Inhibiteurs d'arnmi et leurs utilisations
|
WO2012158757A1
(fr)
|
2011-05-16 |
2012-11-22 |
The Trustees Of The University Of Pennsylvania |
Plasmides pro-viraux pour la production de virus adéno-associé recombinant
|
US9598468B2
(en)
|
2011-05-18 |
2017-03-21 |
University Of Florida Research Foundation, Incorporated |
Polypeptides and vectors for targeting HER2/neu expressing cells and uses thereof
|
BR112013028625A2
(pt)
|
2011-06-06 |
2017-01-24 |
Biocartis Sa |
lise seletiva de células através de tensoativos iônicos
|
WO2012177906A1
(fr)
*
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Dosages et procédés de détermination de l'activité d'un agent thérapeutique chez un sujet
|
WO2013014294A2
(fr)
|
2011-07-27 |
2013-01-31 |
Genethon |
Systèmes d'expression de baculovirus perfectionnés
|
EP2990477B8
(fr)
|
2011-09-08 |
2018-10-31 |
uniQure IP B.V. |
Élimination de virus contaminants de préparations d'aav
|
WO2013036889A1
(fr)
|
2011-09-09 |
2013-03-14 |
University Of Washington |
Peptide de transport rétrograde et son utilisation pour administration au système nerveux central
|
EP2771455B1
(fr)
|
2011-10-28 |
2016-10-05 |
The University of North Carolina At Chapel Hill |
Lignée cellulaire pour la production d'un virus adéno-associé
|
JP6348064B2
(ja)
|
2011-11-22 |
2018-06-27 |
ザ チルドレンズ ホスピタル オブ フィラデルフィア |
効率の高いトランスジーン送達のためのウイルスベクター
|
WO2013078199A2
(fr)
|
2011-11-23 |
2013-05-30 |
Children's Medical Center Corporation |
Méthodes pour une administration in vivo améliorée d'arn synthétiques modifiés
|
WO2013123094A2
(fr)
|
2012-02-14 |
2013-08-22 |
The Regents Of The University Of California |
Administration systémique et expression régulée des gènes à action paracrine pour les maladies cardiovasculaires et autres états
|
BR112014020325A2
(pt)
|
2012-02-17 |
2017-08-08 |
Childrens Hospital Philadelphia |
composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos
|
WO2013130824A1
(fr)
|
2012-02-29 |
2013-09-06 |
Sangamo Biosciences, Inc. |
Procédés et compositions permettant de traiter la maladie de huntington
|
DK2839014T3
(da)
|
2012-04-18 |
2021-03-08 |
Childrens Hospital Philadelphia |
Sammensætning og fremgangsmåder til højeffektiv genoverførsel ved anvendelse af aav-capsid-varianter
|
US20140162319A2
(en)
|
2012-05-02 |
2014-06-12 |
Sangeetha Hareendran |
Nucleotide sequences, methods, kit and a recombinant cell thereof
|
US9163259B2
(en)
|
2012-05-04 |
2015-10-20 |
Novartis Ag |
Viral vectors for the treatment of retinal dystrophy
|
KR102108586B1
(ko)
|
2012-05-08 |
2020-05-07 |
머크 샤프 앤드 돔 코포레이션 |
투과성 글리코시다제 억제제 및 그의 용도
|
EP2847337A4
(fr)
|
2012-05-09 |
2016-04-27 |
Univ Oregon Health & Science |
Plasmides et vecteurs viraux associés à un adénovirus
|
TWI775096B
(zh)
|
2012-05-15 |
2022-08-21 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
|
BR112014028684A2
(pt)
|
2012-05-18 |
2017-07-25 |
Univ Pennsylvania |
subfamília e adenovírus de símio a1302, a1320, a1331 e a1337 e usos dos mesmos
|
CN104603272B
(zh)
|
2012-07-06 |
2017-11-07 |
宝生物工程株式会社 |
能够产生腺伴随病毒载体的细胞
|
CA2878401C
(fr)
|
2012-07-06 |
2022-07-19 |
University Of Iowa Research Foundation |
Compositions de vecteur viral adeno-associe modifiees
|
JP2015524264A
(ja)
|
2012-07-17 |
2015-08-24 |
ユニベルシテ ドゥ ジュネーブ |
遺伝子発現の下方制御のための核酸
|
BR112015002168A2
(pt)
|
2012-08-01 |
2017-11-07 |
Nationwide Childrens Hospital |
liberação intratecal de vírus 9 adeno-associado recombinante
|
AU2013323270B2
(en)
|
2012-09-28 |
2017-09-28 |
The University Of North Carolina At Chapel Hill |
AAV vectors targeted to oligodendrocytes
|
CN104937100B
(zh)
|
2012-12-25 |
2020-04-03 |
宝生物工程株式会社 |
Aav 变体
|
US10000753B2
(en)
|
2013-01-08 |
2018-06-19 |
Benitec Biopharma Limited |
Age-related macular degeneration treatment
|
EP2954051B1
(fr)
|
2013-02-08 |
2019-03-27 |
The Trustees Of The University Of Pennsylvania |
Capsides aav8 modifiées pour transfert génétique pour thérapies rétiniennes
|
JP2016514152A
(ja)
|
2013-03-13 |
2016-05-19 |
ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア |
アデノ随伴ウイルスベクターおよびその使用の方法
|
EP2970966A4
(fr)
|
2013-03-15 |
2016-10-26 |
Univ North Carolina |
Répétitions terminales inversées de synthèse du virus adéno-associé
|
WO2014144844A1
(fr)
|
2013-03-15 |
2014-09-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Petits arn dérivés d'arnt (arnts) impliqués dans la viabilité cellulaire
|
WO2014144486A2
(fr)
|
2013-03-15 |
2014-09-18 |
The Children's Hospital Of Philadelphia |
Vecteurs comprenant des séquences polynucléotidiques de garnissage/de remplissage et leurs procédés d'utilisation
|
CA2909085C
(fr)
|
2013-04-08 |
2023-08-29 |
University Of Iowa Research Foundation |
Vecteur chimerique de parvovirus a virus adeno-asocie /bocavirus
|
EP2792742A1
(fr)
|
2013-04-17 |
2014-10-22 |
Universitätsklinikum Hamburg-Eppendorf (UKE) |
Vecteurs de thérapie génique permettant de traiter la myocardiopathie
|
WO2014170480A1
(fr)
|
2013-04-18 |
2014-10-23 |
Fondazione Telethon |
Administration efficace de grands gènes par des vecteurs aav doubles
|
KR102413498B1
(ko)
|
2013-04-20 |
2022-06-24 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
엑손 2-표적 U7snRNA 폴리뉴클레오티드 작제물의 재조합형 아데노 부속 바이러스 전달
|
WO2015012924A2
(fr)
|
2013-04-29 |
2015-01-29 |
The Trustees Of The University Of Pennsylvania |
Cassettes d'expression préférentielle pour tissus modifiées par un codon, vecteurs les contenant, et utilisation
|
CN105377039A
(zh)
|
2013-05-15 |
2016-03-02 |
明尼苏达大学董事会 |
腺相关病毒介导的基因向中枢神经系统转移
|
WO2014186746A1
(fr)
|
2013-05-16 |
2014-11-20 |
University Of Florida Research Foundation, Inc. |
Éléments d'arnm en épingle à cheveux et procédés de régulation de la traduction des protéines
|
WO2014194132A1
(fr)
|
2013-05-31 |
2014-12-04 |
The Regents Of The University Of California |
Variants de virus adéno-associés et leurs méthodes d'utilisation
|
WO2014201308A1
(fr)
|
2013-06-12 |
2014-12-18 |
Washington University |
Vecteurs adénoviraux ciblant les cellules endothéliales et procédés et utilisations associés
|
US20160122727A1
(en)
|
2013-06-13 |
2016-05-05 |
Shire Human Genetic Therapies, Inc. |
Messenger rna based viral production
|
HUE047996T2
(hu)
|
2013-07-22 |
2020-05-28 |
Childrens Hospital Philadelphia |
AAV variáns és készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez
|
MX2016001026A
(es)
|
2013-07-26 |
2016-08-03 |
Univ Iowa Res Found |
Metodos y composiciones para tratar enfermedades del cerebro.
|
ITTO20130669A1
(it)
|
2013-08-05 |
2015-02-06 |
Consiglio Nazionale Ricerche |
Vettore adeno-associato ricombinante muscolo-specifico e suo impiego nel trattamento di patologie muscolari
|
US11078464B2
(en)
|
2013-08-30 |
2021-08-03 |
Amgen Inc. |
High titer recombinant AAV vector production in adherent and suspension cells
|
ES2739288T3
(es)
|
2013-09-13 |
2020-01-30 |
California Inst Of Techn |
Recuperación selectiva
|
EP3068889B1
(fr)
|
2013-09-26 |
2019-04-17 |
Universitat Autònoma De Barcelona |
Compositions de thérapie génique destinées à être utilisées dans la prévention et/ou le traitement d'une stéatose hépatique non-alcoolique
|
EP3049527A4
(fr)
|
2013-09-26 |
2017-08-16 |
University of Florida Research Foundation, Inc. |
Bibliothèque de capsides aav combinatoire synthétique pour la thérapie génique ciblée
|
PL3459965T3
(pl)
|
2013-10-11 |
2021-07-26 |
Massachusetts Eye & Ear Infirmary |
Sposoby przewidywania sekwencji wirusa-przodka i ich zastosowania
|
EA036394B1
(ru)
|
2013-10-24 |
2020-11-05 |
ЮНИКЬЮРЕ АйПи Б.В. |
Псевдотипированный вектор на основе аденоассоциированного вируса aav-5 для генной терапии неврологических заболеваний
|
EP3066195A4
(fr)
|
2013-11-08 |
2017-06-28 |
The Board of Trustees of the University of Arkansas |
Oncogène "x" de virus adéno-associés
|
JP2016537341A
(ja)
|
2013-11-11 |
2016-12-01 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
ハンチントン病を処置するための方法および組成物
|
CA2930872C
(fr)
|
2013-11-26 |
2022-05-31 |
University Of Florida Research Foundation, Incorporated |
Vecteurs de type virus adeno-associe pour le traitement de maladie du stockage du glycogene
|
KR102245861B1
(ko)
|
2013-11-29 |
2021-04-28 |
다카라 바이오 가부시키가이샤 |
아데노 수반 바이러스의 정량 방법
|
US20170002350A1
(en)
|
2013-12-03 |
2017-01-05 |
Agency For Science, Technology And Research |
Tailed mirtron effectors for rnai-mediated gene silencing
|
GB201322798D0
(en)
|
2013-12-20 |
2014-02-05 |
Oxford Biomedica Ltd |
Production system
|
WO2015106273A2
(fr)
|
2014-01-13 |
2015-07-16 |
Trustees Of Boston University |
Méthodes et dosages concernant la chorée de huntington et la maladie de parkinson
|
GB201401707D0
(en)
|
2014-01-31 |
2014-03-19 |
Sec Dep For Health The |
Adeno-associated viral vectors
|
GB201403684D0
(en)
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
WO2015124546A1
(fr)
|
2014-02-19 |
2015-08-27 |
Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii- Cnic |
Vecteurs aav destinés au traitement des cardiopathies ischémiques et non ischémiques
|
WO2015126972A1
(fr)
|
2014-02-21 |
2015-08-27 |
University Of Florida Research Foundation, Inc. |
Procédés et compositions pour l'administration de gènes à des cellules bipolaires on
|
WO2015127351A1
(fr)
|
2014-02-24 |
2015-08-27 |
Celgene Corporation |
Méthodes d'utilisation d'un activateur du céréblon pour l'expansion de cellules neurales et le traitement de troubles du système nerveux central
|
US10308957B2
(en)
|
2014-03-04 |
2019-06-04 |
University Of Florida Research Foundation, Inc. |
rAAV vectors and methods for transduction of photoreceptors and RPE cells
|
IL247729B2
(en)
|
2014-03-10 |
2023-09-01 |
Uniqure Ip Bv |
Improved aav vectors produced in insect cells
|
EP3750907A3
(fr)
|
2014-03-18 |
2021-04-28 |
University of Massachusetts |
Compositions à base de raav et procédés pour traiter la sclérose latérale amyotrophique
|
EP2933335A1
(fr)
|
2014-04-18 |
2015-10-21 |
Genethon |
Procédé de traitement de neuropathies périphériques et sclérose latérale amyotrophique
|
US10975391B2
(en)
|
2014-04-25 |
2021-04-13 |
University Of Massachusetts |
Recombinant AAV vectors useful for reducing immunity against transgene products
|
BR112016024379A2
(pt)
|
2014-04-25 |
2017-10-10 |
Univ Pennsylvania |
variantes ldlr e seu uso em composições para reduzir os níveis de colesterol
|
EP3137497B1
(fr)
|
2014-05-02 |
2021-04-07 |
Genzyme Corporation |
Vecteurs aav pour thérapie génique de la rétine et du snc
|
AU2015255877B2
(en)
|
2014-05-08 |
2020-03-26 |
Chdi Foundation, Inc. |
Methods and compositions for treating huntington's disease
|
EP3142706A1
(fr)
|
2014-05-16 |
2017-03-22 |
Vrije Universiteit Brussel |
Correction génétique d'une dystrophie myotonique de type 1
|
AU2015264263B2
(en)
|
2014-05-20 |
2021-08-05 |
University Of Iowa Research Foundation |
Huntington's disease therapeutic compounds
|
EP3160980B1
(fr)
|
2014-05-28 |
2020-05-20 |
The Regents of the University of California |
MOLECULES HYBRIDES DE tARN/pre-miARN ET PROCEDES D'UTILISATION
|
WO2015191508A1
(fr)
*
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Capsides chimériques
|
WO2015192063A1
(fr)
|
2014-06-13 |
2015-12-17 |
Yasuhiro Ikeda |
Procédés et matériaux permettant d'augmenter l'infectivité d'un vecteur viral
|
WO2015196179A1
(fr)
|
2014-06-20 |
2015-12-23 |
University Of Florida Research Foundation, Inc. |
Procédés d'encapsulation de plusieurs vecteurs viraux associés aux adénovirus
|
WO2016004319A1
(fr)
|
2014-07-02 |
2016-01-07 |
University Of Florida Research Foundation, Inc. |
Compositions et procédés pour purifier un virus adéno-associé recombinant
|
WO2016006658A1
(fr)
|
2014-07-10 |
2016-01-14 |
タカラバイオ株式会社 |
Procédé de fabrication de particules de virus sans enveloppe
|
US10392622B2
(en)
|
2014-08-01 |
2019-08-27 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for self-regulated inducible gene expression
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
EP3200830B1
(fr)
|
2014-10-03 |
2020-09-09 |
University of Massachusetts |
Vecteurs aav identifiés au moyen de banques à efficacité élevée
|
BR112017007737A2
(pt)
|
2014-10-21 |
2018-01-30 |
Univ Massachusetts |
variantes de aav recombinantes e usos das mesmas
|
CN107106689A
(zh)
|
2014-11-05 |
2017-08-29 |
沃雅戈治疗公司 |
用于治疗帕金森病的aadc多核苷酸
|
SG11201703419UA
(en)
|
2014-11-14 |
2017-05-30 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
MX2017006216A
(es)
|
2014-11-14 |
2018-08-29 |
Voyager Therapeutics Inc |
Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
|
CN114480440A
(zh)
|
2014-11-21 |
2022-05-13 |
北卡罗来纳-查佩尔山大学 |
靶向中枢神经系统的aav载体
|
US10900053B2
(en)
|
2014-11-21 |
2021-01-26 |
University Of Florida Research Foundation, Incorporated |
Genome-modified recombinant adeno-associated virus vectors
|
CN108064292B
(zh)
|
2014-12-24 |
2021-05-04 |
尤尼克尔生物制药股份有限公司 |
RNAi诱导的亨廷顿蛋白基因抑制
|
EP3240577B1
(fr)
|
2014-12-30 |
2023-07-05 |
University of Iowa Research Foundation |
Agent thérapeutique qui active la fonction mtorc1 pour le traitement de la maladie de huntington
|
US10907176B2
(en)
|
2015-01-14 |
2021-02-02 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeted gene transfer
|
EP3632923A1
(fr)
|
2015-01-16 |
2020-04-08 |
Voyager Therapeutics, Inc. |
Polynucléotides de ciblage du système nerveux central
|
CA2975447C
(fr)
|
2015-01-30 |
2021-02-23 |
The Regents Of The University Of California |
Systeme de delivrance de genes sous-pial spinal
|
WO2016126857A1
(fr)
|
2015-02-03 |
2016-08-11 |
University Of Florida Research Foundation, Inc. |
Mutants de recombinaison aav1, aav5 et aav6 et leurs utilisations
|
AU2016219396B2
(en)
|
2015-02-10 |
2022-03-17 |
Genzyme Corporation |
Variant RNAi
|
EA201791803A1
(ru)
|
2015-02-10 |
2017-11-30 |
Джензим Корпорейшн |
Улучшенная доставка вирусных частиц в полосатое тело и кору больших полушарий
|
WO2016137949A1
(fr)
|
2015-02-23 |
2016-09-01 |
Voyager Therapeutics, Inc. |
Expression régulable au moyen du virus adéno-associé (vaa)
|
US20180094280A1
(en)
|
2015-03-20 |
2018-04-05 |
Bluebird Bio, Inc. |
Vector formulations
|
JP6836999B2
(ja)
|
2015-03-24 |
2021-03-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
アデノ随伴ウイルス変異体及びその使用方法
|
US20160319278A1
(en)
|
2015-04-03 |
2016-11-03 |
University Of Massachusetts |
Fully stabilized asymmetric sirna
|
SI3277814T1
(sl)
*
|
2015-04-03 |
2020-12-31 |
University Of Massachusetts |
Oligonukleotidne spojine za ciljanja MRNA huntingtina
|
US10081659B2
(en)
|
2015-04-06 |
2018-09-25 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Adeno-associated vectors for enhanced transduction and reduced immunogenicity
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
WO2016168728A2
(fr)
|
2015-04-16 |
2016-10-20 |
Emory University |
Promoteurs et vecteurs recombinés pour l'expression de protéines dans le foie et utilisation associée
|
EP3285788A4
(fr)
|
2015-04-23 |
2018-12-05 |
University of Massachusetts |
Modulation de l'expression d'un transgène du vecteur aav
|
CA3021949C
(fr)
|
2015-04-24 |
2023-10-17 |
University Of Massachusetts |
Constructions d'aav modifiees et utilisations de celles-ci
|
EP3291765A4
(fr)
|
2015-05-07 |
2019-01-23 |
Massachusetts Eye & Ear Infirmary |
Procédés d'administration d'un agent à l'oeil
|
CN113041451B
(zh)
|
2015-05-11 |
2023-06-09 |
亚克安娜治疗学有限公司 |
药物输送系统和方法
|
JP6805174B2
(ja)
|
2015-05-12 |
2020-12-23 |
アメリカ合衆国 |
神経成長因子シグナルペプチド及び副甲状腺ホルモンを含むaav分離株及び融合タンパク質
|
US20170067028A1
(en)
|
2015-05-15 |
2017-03-09 |
Douglas J. Ballon |
Radiolabeling of adeno associated virus
|
US10729790B2
(en)
|
2015-05-26 |
2020-08-04 |
Salk Institute For Biological Studies |
Motor neuron-specific expression vectors
|
US11027024B2
(en)
|
2015-05-29 |
2021-06-08 |
University Of Iowa Research Foundation |
Methods of delivery of transgenes for treating brain diseases
|
US11266748B2
(en)
|
2015-07-02 |
2022-03-08 |
University Of Florida Research Foundation, Incorporated |
Recombinant adeno-associated virus vectors to target medullary thyroid carcinoma
|
ES2895652T3
(es)
|
2015-07-07 |
2022-02-22 |
Inst Nat Sante Rech Med |
Métodos y composiciones farmacéuticas para expresar un polinucleótido de interés en el sistema nervioso periférico de un sujeto
|
US20170007669A1
(en)
|
2015-07-07 |
2017-01-12 |
Mayo Foundation For Medical Education And Research |
Peptide-mediated delivery of active agents across the blood-brain barrier
|
US20180216133A1
(en)
|
2015-07-17 |
2018-08-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for achieving high levels of transduction in human liver cells
|
CA2988471A1
(fr)
|
2015-07-28 |
2017-02-02 |
University Of Massachusetts |
Expression transgenique de dnase i in vivo fournie par un vecteur de virus adeno-associe
|
DK3872085T5
(da)
|
2015-07-30 |
2024-08-12 |
Massachusetts Eye & Ear Infirmary |
Stam-virussekvenser og anvendelser heraf
|
US20180201937A1
(en)
|
2015-08-04 |
2018-07-19 |
The University Of Chicago |
Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
|
CA2998500A1
(fr)
|
2015-09-23 |
2017-03-30 |
Sangamo Therapeutics, Inc. |
Represseurs htt et leurs utilisations
|
IL292830B2
(en)
|
2015-09-28 |
2023-06-01 |
Univ Florida |
Methods and compositions for stealth virus antibody vectors
|
WO2017062983A1
(fr)
|
2015-10-09 |
2017-04-13 |
The Children's Hospital Of Philadelphia |
Compositions et méthodes pour traiter la maladie de huntington et les troubles apparentés
|
CN108368505B
(zh)
|
2015-10-09 |
2023-02-21 |
建新公司 |
改善的flare(流式细胞术减弱报道蛋白表达)技术用于快速批量分选
|
US10123969B2
(en)
|
2015-10-15 |
2018-11-13 |
Wisconsin Alumni Research Foundation |
Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
|
US11253576B2
(en)
|
2015-10-22 |
2022-02-22 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
US11426469B2
(en)
|
2015-10-22 |
2022-08-30 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
WO2017070476A2
(fr)
|
2015-10-22 |
2017-04-27 |
University Of Florida Research Foundation, Inc. |
Banque de capsides aav3 combinatoire synthétique
|
AU2016341428B2
(en)
|
2015-10-23 |
2021-12-02 |
University Of Iowa Research Foundation |
Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection
|
US11135313B2
(en)
|
2015-10-28 |
2021-10-05 |
The Trustees Of The University Of Pennsylvania |
Intrathecal administration of adeno-associated-viral vectors for gene therapy
|
EP3368054A4
(fr)
|
2015-10-28 |
2019-07-03 |
Voyager Therapeutics, Inc. |
Expression régulable au moyen d'un virus adéno-associé (vaa)
|
WO2017083423A1
(fr)
|
2015-11-10 |
2017-05-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Procédés et compositions pour moduler une infection par le vaa
|
EP3384015A4
(fr)
|
2015-12-01 |
2019-05-29 |
Spark Therapeutics, Inc. |
Procédés susceptibles d'être développés pour la production d'un vecteur viral adéno-associé (aav) dans un système de culture cellulaire en suspension exempt de sérum approprié pour une utilisation clinique système
|
WO2017095753A1
(fr)
|
2015-12-01 |
2017-06-08 |
Invivo Therapeutics Corporation |
Compositions et procédés de préparation d'un milieu injectable à administrer dans le système nerveux central
|
US10406244B2
(en)
|
2015-12-02 |
2019-09-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
AAV vectors with expanded packaging capacity
|
US10385320B2
(en)
|
2015-12-02 |
2019-08-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
Recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism
|
CA3004971A1
(fr)
|
2015-12-03 |
2017-06-08 |
Universite D'evry Val D'essonne |
Compositions et procedes permettant d'ameliorer l'efficacite de vecteurs viraux
|
EP3387117B1
(fr)
|
2015-12-11 |
2022-11-23 |
The Trustees Of The University Of Pennsylvania |
Procédé de purification évolutif d'aav8
|
KR102423442B1
(ko)
|
2015-12-11 |
2022-07-20 |
캘리포니아 인스티튜트 오브 테크놀로지 |
아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
|
US11015173B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV1
|
ES2918998T3
(es)
|
2015-12-11 |
2022-07-21 |
Univ Pennsylvania |
Método de purificación escalable para AAVrh10
|
EP3390429A4
(fr)
|
2015-12-14 |
2019-07-17 |
The University of North Carolina at Chapel Hill |
Protéines capsidiques modifiées pour la libération améliorée de vecteurs parvoviraux
|
CA3011939A1
(fr)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Procede pour ameliorer l'efficacite de l'administration au systeme nerveux central d'un gene aav par voie systemique
|
CA3198936A1
(fr)
|
2016-03-07 |
2017-09-14 |
University Of Iowa Research Foundation |
Expression mediee par aav utilisant un promoteur et un activateur synthetiques
|
CA3018076A1
(fr)
|
2016-03-18 |
2017-09-21 |
The Children's Hospital Of Philadelphia |
Agent therapeutique pour le traitement de maladies, notamment les maladies touchant le systeme nerveux central
|
EP3235516B1
(fr)
|
2016-04-22 |
2019-06-26 |
Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin |
Vecteur de virus adéno-associés (aav) régulable
|
WO2017189963A1
(fr)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions pour le traitement de maladies
|
EP3452495B1
(fr)
|
2016-05-03 |
2021-06-23 |
Children's Medical Research Institute |
Polynucléotides, polypeptides et virions de virus adéno-associé
|
WO2017192750A1
(fr)
|
2016-05-04 |
2017-11-09 |
Oregon Health & Science University |
Vecteurs viraux adéno-associés recombinés
|
KR102392236B1
(ko)
|
2016-05-18 |
2022-05-03 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
AU2018260998A1
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
EP3619308A4
(fr)
|
2017-05-05 |
2021-01-27 |
Voyager Therapeutics, Inc. |
Compositions et méthodes de traitement de la maladie de huntington
|
US20220090127A1
(en)
|
2017-06-02 |
2022-03-24 |
Institut National De La Sante Et De La Recherche Medicale (Inserm |
Viral vector combining gene therapy and genome editing approaches for gene therapy of genetic disorders
|
GB201714027D0
(en)
|
2017-09-01 |
2017-10-18 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of huntington's disease
|
EP3684932A1
(fr)
|
2017-09-22 |
2020-07-29 |
Genzyme Corporation |
Variant d'arni
|
JP7502991B2
(ja)
|
2017-10-16 |
2024-06-19 |
ボイジャー セラピューティクス インコーポレイテッド |
筋萎縮性側索硬化症(als)の治療
|
CA3107462A1
(fr)
|
2018-07-24 |
2020-01-30 |
Voyager Therapeutics, Inc. |
Systemes et methodes de production de formulations de therapie genique
|
US20220275367A1
(en)
|
2019-07-24 |
2022-09-01 |
Voyager Therapeutics, Inc. |
Compositions and methods for treating huntington's disease
|